Tubulointerstitial fibrosis is the consequence of an injury characterized by the accumulation of excess collagen and other extracellular matrix components, resulting in the destruction of the normal kidney architecture and subsequent loss of function. A transcription factor Sp1, originally described as a ubiquitous transcription factor, is involved in the basal expression of extracelluar matrix genes and may, therefore, be important in fibrotic processes. Here, we report on the design of a ring-Sp1 decoy oligonucleotide, containing the consensus Sp1 binding sequence in a single decoy molecule without an open end, to create a novel therapeutic strategy for fibrosis. The ring-Sp1 decoy oligonucleotide is highly resistant to degradation by nucleases or serum compared to the conventional phosphorothioated doublestranded Sp1 decoy oligonucleotide, and effectively suppressed the expression of transforming growth factor-b1 and fibronectin, the binding of Sp1 to the promoter region of these genes, and proliferation in response to serum in normal rat kidney fibroblasts. Moreover, treatment with the ring-Sp1 decoy in vivo significantly attenuates extracellular matrix gene expression in the rat kidney in which a unilateral ureteral obstruction had been induced. These results suggest that the ring-Sp1 decoy oligonucleotide represents promising therapeutic alternative to the conventional treatment of fibrotic disorders.
Introduction
Renal interstitial fibrosis is a progressive and potentially disease that is caused by diverse clinical entities including urinary tract obstruction, chronic inflammation, and diabetes. 1, 2 It has been reported that tubulointerstitial injury is a more consistent predictor of functional impairment than glomerular damage. 3 Fibrotic structural derangement of the tubulointerstitial compartment occurs in virtually progressive renal disease. Interstitial fibrosis is characterized by the accumulation of matrix proteins in the renal tubulointerstitial compartment. Among the proposed mechanisms by which the renal injury progresses, transforming growth factor (TGF)-b1 is postulated to play a central role in the development of tubulointerstitial fibrosis as well as glomerulosclerosis. 4 TGF-b1 has been demonstrated to have multiple biological functions, especially in renal disease. It is mainly released from platelets, macrophages, and lymphocytes, and is known to stimulate the production of collagen and fibronectin (FN) by fibroblasts in vitro. [5] [6] [7] [8] TGF-b1 also promotes connective tissue deposition in vivo, through the enhanced synthesis of extracellular matrix (ECM) proteins and the inhibition of their degradation. 9, 10 Elevated renal expression of TGFb1 has been clearly demonstrated in almost all experimental models of renal injury characterized by fibrosis. 5, 11 These studies provide plausible evidence in support of the role of TGF-b1 and its downstream pathway as a potential therapeutic target against renal fibrosis.
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Sp1 is a family of ubiquitous transcription factors that are largely associated with GC-rich promoters, and is mainly involved in basal promoter activity. 13 Sp1 exists in a variety of isoforms which bind with varying affinities to sequences designated as Sp1 sites, making up a transcriptional network that plays an important role in the fine tuning of gene expression. Sp1-dependent transcription is altered during cell growth through gene expression.
14 Sp1 has been recognized as a basal factor required for activating the transcription of TATA-less promoters of cell cycle regulators including DHFR, thymidine kinase, and DNA polymerase. 15, 16 Sp1 family members and E2F, another family of transcription factors, cooperatively activates transcription through physical interaction or a cis-acting mechanism, and regulate exit from and the progression of the cell cycle. [17] [18] [19] [20] Specifically, pRb stimulates the transcription of c-myc and c-fos through the binding of Sp1 to their promoter elements. [21] [22] [23] Thus, Sp1 factors are mainly involved in growth-related signal transduction pathways including apoptosis, angiogenesis, and tumorigenesis. 24, 25 The transcription of TGF-b1 is regulated through Sp1 binding to GC-rich sites in the promoter. 26, 27 Several studies have reported that Sp1 regulates the expression of several genes that are relevant to human pathologies, including vascular endothelial growth factor (VEGF), type-I collagen (COL1A2) and downstream targets of TGF-b1, such as plasminogen-activator inhibitor type-1 (PAI-1), urokinase-type plasminogen activator (uPA), and uPA receptor. [28] [29] [30] [31] [32] [33] Recently, decoy technology has been developed in an attempt to reduce the activity of a specific transcription factor through the use of a synthetic double-stranded oligodeoxynucleotide (ODN) containing the consensus binding sequence of a transcription factor. 34 Decoy technology has been proposed as a novel therapeutic tool for use in molecular medicine for treating several disorders. 29, [34] [35] [36] We previously demonstrated that E2F and the AP-1 ring-type decoy ODN efficiently inhibited the expression of specific genes in vivo, and that the E2F decoy ODN effectively inhibited the growth of human tumor cells and cell proliferation in mesangial cells. 37, 38 The Sp1 decoy prevents tumor necrosis factor (TNF)-a from inducing VEGF, TGF-b1, and tissue factor in cancer cells, and inhibits COL1A2 promoter activity in cultured fibroblast and in vivo. 29, 32 In another report, the Sp1 decoy was found to the inhibit angiotensin II-induced expression of the PAI-1 gene and the high glucoseinduced expression of TGF-b1 and the PAI-1 gene in mesangial cells, but its action in renal interstitial fibroblasts in vivo and in vitro remains to be elucidated. 31, 39 In the present study, we report on the design of a R-Sp1 decoy ODN, an improved ring-type decoy ODN containing the consensus Sp1 binding sequence in a single decoy molecule without an open end, and demonstrate that the R-Sp1 decoy ODN blocks the transcription of TGF-b1 and its downstream target genes in cultured kidney fibroblasts. The findings also show that the R-Sp1 decoy ODN when introduced in vivo using a virus vector, effectively reduced ECM production and interstitial fibrosis during the progression of obstructive nephropathy. Our study provides proof for the effectiveness of a gene therapy-based approach on renal fibrosis, using the Sp1 transcription factor as a target.
Results

Construction of ring-type Sp1 decoy ODN with enhanced stability in vitro
Ring-Sp1 (R-Sp1) decoy ODN containing the consensus Sp1 binding sequence (GGGGCGGGGC) in a single decoy molecule without an open end was designed (Figure 1a) . The stabilities of the decoy ODN were initially determined by examining their ability to resist degradation by nucleases. Both R-Sp1 and the PS-Sp1 decoy ODN were found to be resistant to S1 nuclease, which digests singlestranded regions of DNA, suggesting that the stem regions of R-Sp1 and PS-Sp1 decoy ODN were resistant to S1 nuclease (Figure 1b) . We also found that the R-Sp1 decoy ODN was resistant to exonuclease III, while the PS-Sp1 decoy ODN was completely degraded after a 2-h incubation with exonuclease III. The R-Sp1 decoy ODN was somewhat degraded after 24 h incubation with either human serum or FBS, compared with R-Sp1 decoy ODN without either human serum or FBS, while the PS-Sp1 decoy ODN was significantly hydrolyzed by the incubation for 24 h with them. These results indicate that the R-Sp1 decoy ODN is more stable and effective in living cells than the PS-Sp1 decoy. We also checked the transfection efficiency of the Sp1 decoy ODN in NRK-49F cells. Cells were transfected with FITC-labeled Sp1 ODN combined with the Lifofectamine Plust reagent and then examined by fluorescence microscopy. As shown in Figure 1c , we detected FITC-labeled ODN in the nuclei of cells.
Suppressive effects of R-Sp1 decoy ODN in normal rat kidney fibroblasts in vitro EMSA was performed with nuclear extracts of NRK-49F cells that had been transfected with Sp1 decoy ODN to determine the effect of the decoy on the serum stimulation-induced DNA binding activity of Sp1 (Figure 2a ). The binding activity was quantified by a phospho-image analyzer (Figure 2b ). The culturing of NRK-49F cells with serum stimulation resulted in a significant increase in DNA binding activity to the consensus sequence for Sp1 in the nuclear cell extract. The binding is specific, as evidenced by the complete suppression of the formation of the DNA-protein complexes by in the presence of an excess of unlabeled competitor ODN. Transfection with R-Sp1 decoy ODN, but not with the M-Sp1 decoy ODN, significantly attenuated the DNA binding activity induced by serum stimulation. The PS-Sp1 decoy ODN was less effective than R-Sp1 ODN. The incubation of The effects of the Sp1 decoy ODN on promoter activity were examined using three reporter plasmids that were introduced into NRK-49F cells. Initially, we assessed the effect of the Sp1-decoy ODN on the promoter activity of a reporter gene plasmid, Sp1-luc, which contains six tandem copies of the Sp1-binding sites in the promoter ( Figure 3a ). As expected, cotransfection of R-Sp1 decoy significantly attenuated the enhanced luciferase gene expression induced by serum stimulation, while the M-Sp1 decoy had a negligible effect on luciferase activity. Similar inhibitory effects of Sp-1 decoy ODNs on promoter activity were observed in experiments in which reporter plasmids containing intrinsic ECM promoters such as TGF-b1 (p3TP-lux, Figure 3b ) and FN were used (FN-luc, Figure 3c ).
The effect of the R-Sp1 decoy ODN on the endogenous mRNA expression of TGF-b1 and FN in NRK-49F cells was examined by Northern blot, and the results were quantified by densitometric analysis (Figure 4 ). Serum stimulation significantly increased the endogenous transcription of TGF-b1 and FN, and the transfection of NRK-49F cell with the R-Sp1 decoy ODN, but not with the M-Sp1 decoy ODN, resulted in a significant attenuation in the serum stimulation-induced expression of these genes. Again, the effect was more significant than PS-decoy ODN. Additionally, we have confirmed that VEGF and PAI-1 expression, in NRK49F cells, was decreased by R-Sp1 decoy oligonucleotide compared with PS-Sp1 decoy & M-Sp1 decoy oligonucleotides, as evidenced by RT-PCR analysis (data not shown).
Finally, we determined the effect of the R-Sp1 decoy ODN on NRK-49F cell proliferation promoted by serum stimulation ( Figure 5 ). Transfection with the R-Sp1 decoy ODN, but not with the M-Sp1 decoy ODN, resulted in a significant inhibition of cell growth stimulated by serum. Again, the PS-Sp1 decoy ODN was much less effective than the R-Sp1 decoy ODN. Collectively, these results suggest that the R-Sp1 decoy ODN effectively blocks Sp1-mediated transcription and suppresses the proliferation of NRK-49F cells. 
Reduction in ECM accumulation by Sp1 decoy ODN treatment ameliorates renal tubulointerstitial fibrosis
To determine the transfection efficiency in vivo, the Sp1 decoy ODN was labeled using the Label IT s fluorescein nucleic acid kit (Mirus). FITC-labeled ODN was introduced into the left kidney of normal rats via the renal vein by the HVJ-liposome method. Green fluorescence was observed in the interstitial areas, throughout the left kidney even 7 days after the introduction ( Figure 6 ). In rats that had received unilateral ureteral obstruction (UUO) surgery, the kidneys developed tubular atrophy and epithelial flattening with tubulointerstitial fibrosis as evidenced by Masson's trichrome staining (Figure 7a ). Quantitative analysis of the fibrotic area, determined by blue staining, demonstrates that the suppressive effect of R-decoy ODN in the obstructed kidneys is statistically significant when compared to a vehicletreated control (7.570.8 versus 12.370.8%; Po0.01; n ¼ 9; Figure 7b) .
To explore the role of ECM accumulation in tubulointerstitial fibrosis, we examined the effect of R-Sp1 decoy ODN by Northern blotting. Figure 8 illustrates the expression of TGF-b1, FN and VEGF mRNA in the whole kidney on day 7 after ureteral ligation. All mRNAs for TGF-b1, FN and VEGF were markedly elevated in obstructed kidneys from the rats that had been treated with vehicle as compared with the sham-operated kidneys. On the other hand, introduction of the R-Sp1 decoy ODN into the kidney significantly inhibited mRNA expression of TGF-b1, FN and VEGF compared with the vehicle-treated obstructed kidney. However, such a significant suppressive effect was not observed in rats treated M-Sp1 decoy ODN. PS-Sp1 decoy ODN somewhat inhibited TGF-b1, FN and VEGF mRNA expression compared with the vehicle-treated obstructed kidney and M-Sp1 decoy ODN. The transcript levels of GAPDH mRNA expression remained unaffected in all groups. These results clearly show that R-Sp1 decoy downregulates the expression of TGF-b1, FN and VEGF in UUO model, indicating that the transcription of three gene is regulated by Sp1 binding site in their promoter. Figure  9 illustrates the expression of TGF-b1, FN and VEGF, as evidenced by immunohistochemical study, in the whole kidney on day 7 after ureteral ligation. A computational analysis of histological staining demonstrated that the suppressive effect of R-Sp1-decoy ODN treatment, but not that of the M & PS-Sp1 decoy ODN treatment, is statistically significant.
These results suggest that R-Sp1 decoy ODN represents a potentially effective gene therapy to ameliorate interstitial fibrosis in obstructive nephropathy.
Discussion
Using several complementary approaches, we demonstrated that Sp1 targeting may represent a powerful therapeutic approach to reduce ECM accumulation under fibrotic conditions. We have determined the relative stability of the Sp1 decoy ODN by examining its ability to resist degradation by nucleases. R-Sp1 decoy ODN was found to be resistant to exonuclease and FBS, exhibiting a significantly enhanced stability compared to the PS-Sp1 decoy ODN. This improvement provides the decoy ODN a great advantage in synthetic efficiency, as well as in effectiveness in vivo.
EMSA showed that the DNA-protein complex induced by serum stimulation was reduced significantly in NRK-49F cells that had been transfected with R-Sp1 decoy ODN whereas the M-Sp1 decoy ODN had no effect on DNA binding activity. Experiments using reporter plasmids that contain the Sp1 binding motif in the TGF-b1 and FN promoter demonstrate that the enhancement in Sp1-dependent transcription activity in response to serum stimulation was reduced significantly by the R-Sp1 decoy ODN. In addition, the R-Sp1 decoy ODN suppressed the mRNA generation of TGF-b1 and FN as well as cell proliferation induced by serum stimulation.
We also demonstrated that R-Sp1 decoy ODN treatment in vivo effectively attenuated the induction of TGF-b1 and FN mRNA expression and the resulting deposition of TGF-b1 and ECM in tubulointerstitial area of a rat that had received UUO surgery and that the treatment ameliorated tubulointerstitial fibrosis. It has been reported that a highly effective HVJ-liposome gene transfer technique introduced decoy ODN mainly into renal interstitial fibroblasts. 40 Together with the present results, this suggests that this strategy specifically suppresses Sp1-mediated transcription in the interstitial areas of the targeted kidney, and thus can be used as an effective therapy for tubulointerstitial fibrosis caused in nephritic diseases.
Sp1 regulates the expression of a vast variety of genes, including TGF-b, fibrogenic cytokine, and a wide variety of matrix gene. 26, 32 We have particularly focused on its role in renal fibrogenesis activated by TGF-b1, because TGF-b1 levels are increased in both the human and experimental fibrosis models (UUO), and this prosclerotic cytokine has been implicated as a major mediator of nephropathy.
31,39 TGF-b1 exerts its physiological effect by 
Suppression of rat kidney fibrosis by Sp1 decoy
Y-M Chae et al the induction of subsequent downstream targets including matrix proteins and PAI-1, and subsequently contributes to the progression of nephritic fibrosis. 31 We selected a decoy system that targets Sp1 function for several reasons. First, Sp1 binding sites are present in the promoter of TGF-b1 and its receptors. 41 Sp1 consensus sites are also present in several promoters of the downstream targets of TGF-b1, and are required to support TGF-b1-mediated transcription activation. 42, 43 In addition, Sp1 directly contributes to the expression of a wide variety of matrix genes. 32 Our present results provide additional evidence to support for the crucial role of Sp1 in nephritic fibrosis.
Materials and methods
Cell culture, gene transfection and luciferase assay
Normal rat kidney fibroblasts (NRK-49F cells) was obtained from the American Type Culture Collection (Rockville, MD) and cultured in DMEM (GIBCO BRL, Rockville, MD, USA) containing 10% fetal bovine serum (FBS; JRH, KS, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin. For serum stimulation, cells at B80% confluence were made quiescent in serum-free DMEM. After 24 h of serum starvation, cells were fed fresh culture medium for 24 h, washed twice with Opti-MEM (Gibco BRL) prior to the experiment, and transfected 
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with 100 nM of Sp1 decoy ODN combined with LipofectAMINE Plust (molar ratio DNA:lipid ¼ 1:3) (Gibco BRL). The decoy ODN:lipid mixture was added dropwise to cells, according to the manufacturer's instructions. After incubation at 371C for 5 h, the cells were cultured in fresh medium containing 1% serum or 10% serum, and maintained until use. The luciferase-reporter plasmid, Sp1-luc, which contains three consensus Sp1-binding sites, was a kind gift from Dr Peggy J Farnham. 44 The promoter region (nucleotide À531/+1) of the rat FN gene was amplified by PCR from Wistar rat genomic DNA with the following primers: forward, 5 0 -GGA CAA GGT AGT GGC CAC TTA ACG-3 0 and reverse, 5 0 -GCG GCT GAG CCC CAA GAG CAG AGG-3 0 . The PCR product of the expected size was subcloned into pGEM-T-Easy vector (Promega, Madison, WI, USA) to construct pGEM-T-FN. pGL3-Basic vector (Promega) was digested with HindIII, then blunted with Klenow fragment, and ligated with EcoRI-Linker (Takara, Tokyo, Japan). The rat FN promoter region was cleaved with EcoRI form pGEM-T-FN and inserted into the EcoRI sites of pGL3-Basic vector (FN-Luc). The sequence of FN-Luc reporter plasmid was confirmed by DNA sequencing. p3TP-lux (TGF-b1 promoter construct) was described previously. 45 To analyze luciferase expression, the cells were washed twice with PBS and lysed in 200 ml of 1 Â reporter lysis buffer (Promega). Each lysate (50 ml) was examined for luciferase activity by means of a commercial kit (Promega).
Construction of ring-type Sp1 decoy ODN
The sequences of Sp1 decoy ODN including phosphorothioated double-stranded ODN (PS-Sp1 decoy), ring Sp1 decoy ODN (R-Sp1 decoy) and mutated Sp1 decoy ODN (M-Sp1 decoy) were as follows: PS-Sp1 decoy (note: consensus sequences are underlined),
0 . These ODN were annealed for 2 h, while the temperature decreased from 80 to 251C. The R-Sp1 decoy ODN was predicted to form a stem-loop structure. Following the addition of T4 DNA ligase (1 U), the mixture was incubated for 24 h at 161C to generate a covalently ligated ring-type decoy molecule.
Stability test for decoy ODN
To examine the stability of the Sp1 decoy ODN, 1 mg PSSp1 decoy ODN and R-Sp1 decoy ODN were incubated with human serum, FBS, exonuclease III, or S1 nuclease. All sera were used without heat inactivation to preserve DNase activity. Each serum sample was diluted by 50% when added to ODN in a 100 ml reaction volume, and mixtures were incubated for 24 h at 371C. Exonuclease III (Takara, Otsu, Japan) at 160 U/mg oligodeoxynucleotide and S1 nuclease (Takara) at 10 U/mg oligodeoxynucleotide were incubated with ODN for 2 h at 371C and for 30 min at 251C, respectively. The Resulting ODN was extracted with phenol chloroform mixture, and examined on a 15% nondenaturing polyacrylamide gel.
To determine the transfection efficiency NRK-49F cells were seeded at 2 Â 10 4 cells/well in twowell chamber slides (NUNC, Inc., Naperville, IL, USA) and cultured in DMEM complete medium for 24 h. The cells were serum-starved for 24 h in DMEM containing 0.5% FBS and transfected with fluorescein-labeled-Sp1 decoy ODN. Sp1 decoy ODN was labeled using the Label IT Fluorescein Nucleic Acid Labeling Kit (Panvera Corp., Madison, WI, USA). The fluorescein-labeled-Sp1 decoy ODN was used to facilitate the transfection of Sp1 decoy ODNs into NRK-49F cells. Briefly, 0.5 mg of Sp1 decoy ODN in DMEM (Gibco BRL, Gaithersburg, MD, USA) Sp1 decoy ODN was mixed with Lifofectamine Plust (Invitrogen, Carlsbad, CA, USA) reagent and transfected by a slightly modified supplier protocol. The Sp1 decoy ODNs-liposome mixtures were added by dropping them into each well followed by incubation at 371C for 24 h. The NRK-49F cells were then washed three times with phosphate-buffered saline (PBS) and fixed in methanol at 41C for 10 min. The cells were mounted and observed by fluorescence microscopy.
Electrophoretic mobility shift assay (EMSA)
The EMSA of the nuclear extract prepared from NRK-49F cells was performed using the double-stranded synthetic ODN containing the Sp1 binding site. (Nucleotide sequences are shown in Figure 1 ) In a typical experiment, DNA probes labeled with [g-32 P]ATP (Amersham, Little Chalfont, UK) and T4 polynucleotide kinase (Promega) were incubated with 6 mg nuclear extract, 100 mg/ml poly dI:dC, 10 mM Tris/HCl (pH 7.5), 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 1 mM MgCl 2 , and 4% glycerol. After the incubation, samples were charged on 4% native polyacrylamide gels with a 0.5 Â TBE running buffer (45 mM Tris, 45 mM boric acid, and 1 mM EDTA) and visualized by autoradiography. In some experiments, a 50-to 10-fold molar excess of cold competitor was added to the reaction mixture before adding the nuclear extracts. For supershift experiments, 3 mg of antibody against Sp1 (Santa Cruz Biotechnologies, Santa Cruz, CA) was added to the reaction mixture and was incubated for 1 h at 41C prior to the addition of the probe.
Cell proliferation
In all, 3000 NRK-49F cells were seeded on tissue culture plates. At 20-50% confluence, NRK-49F cells were rendered quiescent by incubation for 24 h in growth medium deficient in insulin and serum. To evaluate the effect of the Sp1 decoy ODN on NRK-49F cell proliferation, LipofectAMINE Plus:decoy ODN (100 nM) (Gibco BRL) was added to the wells, and cells were incubated at 371C for a further 5 h. Cell proliferation was determined with a WST cell counting kit (Wako, Osaka, Japan).
Preparation of hemaggluting virus of Japan (HVJ) liposome
HVJ liposomes were prepared as described previously. 40 Briefly, egg yolk phosphatidylcholine (Sigma), dioleolyphosphatidylethanolamine (Avanti Polar Lipid, Birmingham, AL, USA), egg yolk sphingomyelin (Sigma), bovine brain phosphatidylserine (Sigma), and cholesterol (Sigma) were mixed in a molar ratio of 16.7:16.7:16.7:10:50 and dissolved in chloroform at a concentration of 30 mM. The lipid mixture (500 ml, 15 mmol) was transferred to a glass tube and dried as a thin lipid film by evaporation. The dried lipid was hydrated in 200 ml of balanced salt 
Unilateral ureteral obstruction (UUO) with gene transfer
All the experimental procedures were in accordance with the institutional guidelines for animal research. In brief, male Sprague-Dawley rats 200-250 g in weight were subjected to either UUO or a sham operation. In UUO rats under pentobarbital anesthesia, the left ureter was ligated with 4-0 silk at two points. After ligation, 1 ml of HVJ-liposome suspension, which contained approximately 200 mg of Sp1-decoy ODN, was injected into the left kidney via the renal vein at the injection fluid speed of 100 ml HVJ-liposome suspension per second using a 24-gauge SURFLO intravenous catheter (Terumo, Tokyo, Japan), after clamping the left renal vein. Blood flow was reestablished at 5 min after the injection. 46 Rats were killed at 3, or 7 days after UUO or the sham operation (n ¼ 7 at each time point). For the sham operation, vehicle was injected into the kidney without ureteral ligation. To assess the transfection efficiency and site of ODN introduced, a HVJ-liposome solution including FITClabeled ODN was injected into the left kidney via the left renal vein. Kidneys on both sides were removed at 20 min after injection. Cryostat sections (4-mm-thick) of unfixed snap-frozen specimens were examined by fluorescence microscopy.
RNA preparation and Northern blot analysis
The kidneys were perfused with cold PBS, and the cortex was removed, snap frozen in liquid nitrogen, and stored at À801C until use. The renal tissue was homogenized with a polytron homogenizer (Kinematica, Switzerland) in TRIzol reagent (GIBCO BRL, Gaithersburg, MD, USA). Total RNA was prepared by an acid guanidinium thiocyanate-phenol-chloroform extraction procedure according to the manufacturer's instructions. For Northern analysis, 20 mg aliquots of total RNA were separated on 1% agarose-formaldehyde gels, transferred to nylon membranes (Hybond-N+; Amersham, Boston, MA, USA), and cross-linked by ultraviolet irradiation. Partial clones of rat TGF-b1 cDNA, FN cDNA, VEGF cDNA, and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA were labeled by a random priming method using [a-32 P] dATP (3000 Ci/mmol; Amersham). Hybridization was carried out at 421C overnight in 50% formamide, 10 Â Denhardt's solution, 1% SDS, 5 Â standard saline citrate (SSC), 50 mM sodium phosphate, and 200 mg/ml salmon sperm DNA. The blots were washed three times at 501C in 0.5 Â SSC with 0.1% SDS, and the signals were quantified by laser densitometry (Scanningimager; Molecular Dynamics, Sunnyvale, CA, USA). Loading differences were normalized using an 18 s rRNA.
Histology and immunohistochemisty
For histological analysis, sagittal kidney sections were fixed with 4% buffered formaldehyde and embedded in paraffin. Sections (2-mm-thick) were stained with Masson's trichrome. The fibrotic area was measured quantitatively using a computer-aided manipulator (KS400, Carl Zeiss Vision) with slight modification. The results were expressed as the percentage area of interstitial fibrosis. For the immunohistochemical analysis of TGFb1, FN, VEGF and a-smooth muscle actin (a-SMA), the sections were deparaffinized, washed with PBS, and treated with 3% H 2 O 2 in methanol for 10 min. The samples were incubated with a rabbit polyclonal anti-TGF-b1 antibody Cell Science, MA, USA), a rabbit polyclonal anti-FN antibody (Santa Cruz Biotechnology, H-300), a rabbit polyclonal anti-VEGF antibody (Santa Cruz Biotechnology, 147), or a mouse monoclonal a-SMA antibody (DAKO Japan, Kyoto, Japan) for 1 h. After the incubation with a biotin-conjugated secondary antibody, the specimens were processed using LSAB+ kit (DAKO) and developed with 3,3 0 -diaminobenzidine tetrahydrochloride.
Statistical analyses
Data are expressed as the mean7s.e.m. Statistical analyses were performed using one-way ANOVA. Po0.05 was considered to be statistically significant.
Abbreviations
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